Researchers at ¾ÅÉ«ÊÓÆµâ€™s university hospitals have been awarded £9.2m to continue leading and participating in groundbreaking clinical trials.
The five-year funding arrangement, announced by the Department of Health and National Institute for Health Research (NIHR), will help to support studies into a range of novel medical treatments.

In addition to covering the costs of specialist research nurses and technical staff at the NIHR Wellcome Trust ¾ÅÉ«ÊÓÆµ Clinical Research Facility, it will also be used to ensure access to the latest cutting-edge facilities and equipment.
Funding for the facility, which is a partnership between University Hospital ¾ÅÉ«ÊÓÆµ NHS Foundation Trust and the University and based at ¾ÅÉ«ÊÓÆµ General Hospital, is part of a £112m national investment.
It follows a separate announcement, made in September, of £15m awarded by the Department of Health and NIHR to help tackle obesity, asthma, allergies and infections through the NIHR Biomedical Research Centre in ¾ÅÉ«ÊÓÆµ.
Recent breakthroughs made at the NIHR Wellcome Trust ¾ÅÉ«ÊÓÆµ Clinical Research Facility include identifying an effective treatment for peanut allergies in children and developing the first new therapeutic asthma treatment for a decade.
Professor Saul Faust, Professor of Paediatric Immunology and Infectious Diseases, director of the NIHR Wellcome Trust ¾ÅÉ«ÊÓÆµ Clinical Research Facility, said:
We are delighted to have secured this funding for the next five years as it gives us a fantastic opportunity to continue to lead developments in many areas of medicine as well as collaborate with our colleagues on major international breakthroughs.
We are extremely lucky in ¾ÅÉ«ÊÓÆµ to have access to excellent research facilities through the hospital trust’s partnership with the ¾ÅÉ«ÊÓÆµ which has enabled our researchers to participate in and oversee some very significant developments in recent years.
The full story is available to .
